Gaining the best understanding of data from clinical trials is key to the development of any new drug. We have been impressed with the experience and support that Exploristics provided us on our oncology and COVID-19 studies, with meaningful insights generated to inform decisions along the development path.

"He is often assigned the most challenging statistical problems faced within the department. In this regard he has demonstrated himself to be fearless, dedicated and excellent in his work. I am consistently impressed with the quality and speed with which he delivers results. I consider myself extremely fortunate to work with him, he is one of my best staff entrusted with the highest priority work and he deserves to be recognised as an excellent employee."

“KerusCloud simulations are very intuitive. You can have a quick understanding of what the goals are, what the outputs could be, and it enables quick decision-making from the whole team regardless of their statistical background.”

“Exploristics has provided excellent service on the Bayesian extrapolation of efficacy in pediatric patients. This is a highly technical expertise that several preferred vendors could not provide when we sought bids from them for this project. The statistical analysis proposal was very clear and cogent that I believe would meet PDCO expectations to discharge the PIP commitment when the regulatory report is filed. I can’t say enough it was an absolute pleasure to work with the team at Exploristics!”

The Kerus simulation tool is very powerful! The simulations for our pivotal trials showed us a suitable and straight forward path to reach marketing approval with a smaller number of patients and quicker compared to our original plans. Discussions with statistic experts from CROs, investigators and key opinion leaders confirmed the approach.

“The KerusCloud platform has proved to be a core part of our decision-making as it allows us to prospectively tailor study designs as new information becomes available.”

“Our experience of working with Exploristics was overwhelmingly positive. The thinking around the company’s objectives from the study took it beyond a number crunching exercise to a more informed and nuanced service that added value to the study and the business. I was also impressed by the flexibility on responding to questions from the Board and others to get us over the line. I hope we have a reason to work together again.”

“We were pleased to partner with the Exploristics team on our trial design and statistical analysis, which has greatly contributed to the efficiency of the programme. KerusCloud allowed us to develop our study design to recognise the transformative potential of EXN407 whilst ensuring we account for and minimise any potential risks. We thank Aiden and the team for their collaborative model and expertise throughout this project.”

“We have had the honour of partnering with Exploristics to develop a statistical plan in support of an innovative Phase 2b neonatology trial. With a paucity of drug development in neonatology and even fewer approvals, their ability to develop a plan accounting for the nuances of neonatal drug development yet utilising robust statistical methods has paved the way for the best possible outcome. Their team is capable and committed to following the program through its journey, allowing us to leverage robust learnings across time. Further, their FSP model has served our needs well. It is a cost-effective and scalable model that allows our Exploristics colleagues to function as members of our team. We highly recommend Exploristics for its reliable and high-quality biostatistical support. Partnering with them has been transformative for our program at Oak Hill Bio.”